Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ACELYRIN Inc | SLRN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.39 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 4.14 - 29.88 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 4.39 | USD |
ACELYRIN Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
427.32M | 97.34M | - | 0 | -381.64M | -3.92 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ACELYRIN News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SLRN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.67 | 5.00 | 4.37 | 4.62 | 609,276 | -0.28 | -6.00% |
1 Month | 5.10 | 5.1338 | 4.14 | 4.51 | 881,848 | -0.71 | -13.92% |
3 Months | 7.53 | 8.885 | 4.14 | 6.63 | 1,216,008 | -3.14 | -41.70% |
6 Months | 8.79 | 9.00 | 4.14 | 6.91 | 1,197,047 | -4.40 | -50.06% |
1 Year | 22.80 | 29.88 | 4.14 | 11.32 | 1,105,497 | -18.41 | -80.75% |
3 Years | 23.00 | 29.88 | 4.14 | 11.97 | 1,117,661 | -18.61 | -80.91% |
5 Years | 23.00 | 29.88 | 4.14 | 11.97 | 1,117,661 | -18.61 | -80.91% |
ACELYRIN Description
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California. |